Morphic announces corporate highlights and financial results for the first quarter 2023

-in emerald-1 phase 2a trial in patients with ulcerative colitis, morf-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed-
MORF Ratings Summary
MORF Quant Ranking